Ophirex, Inc.

📍 Corte Madera, United States🗓 Founded 2015👥 21 employees💰 Last funded May 2022
Biotechnology🌐 ophirex.com
Website LinkedIn
Ophirex, Inc., a Public Benefit Corp. focused on treatments for acute, life-threatening illnesses, is modernizing the treatment of snakebite victims by developing an affordable, accessible, oral treatment for immediate use anywhere a snake’s bite occurs. Approximately 80% of the world’s population lives in close proximity to at least one venomous snake species and more than 500,000 people are killed or maimed by snakes each year worldwide.[1][2] Field treatments could help save hundreds of thousands of lives and limbs annually and provide enormous savings in healthcare costs.[2][3] Ophirex is developing a “time of bite” oral snakebite treatment that blocks the most commonly lethal component of snake venom—present in 95% of the world’s venomous snakes.[4] This antidote—now in human clinical trials—can be administered immediately in the field or in the hospital to effectively stop the venom’s devastating assault.[5][6][7] 1. Vulnerability to snakebite envenoming: a global mapping of hotspots. www.thelancet.com/journals/lancet/article/PIIS0140-6736(18)31224-8/fulltext 2. Strategy for a globally coordinated response to a priority neglected tropical disease: Snakebite envenoming. https://doi.org/10.1371/journal.pntd.0007059 3. Snakebite: An Exploratory Cost-Effectiveness Analysis of Adjunct Treatment Strategies. www.ajtmh.org/view/journals/tpmd/99/2/article-p404.xml 4. A Review and Database of Snake Venom Proteomes. https://pubmed.ncbi.nlm.nih.gov/28927001/ 5. Varespladib (LY315920) Appears to Be a Potent, Broad-Spectrum, Inhibitor of Snake Venom Phospholipase A2 and a Possible Pre-Referral Treatment for Envenomation. https://pubmed.ncbi.nlm.nih.gov/27571102/ 6. Varespladib (LY315920) and Methyl Varespladib (LY333013) Abrogate or Delay Lethality Induced by Presynaptically Acting Neurotoxic Snake Venoms. www.ncbi.nlm.nih.gov/pmc/articles/PMC7076770/ 7. Broad-spectrum Rapid Antidote: Varespladib Oral for Snakebite (BRAVO). https://clinicaltrials.gov/ct2/show/NCT04996264
1
Total investors
0
Early stage
0
Mid stage
1
Late stage
2015
Founded

Investors

1 investors
All
Early stage
Mid stage
Late stage
Investor geography1 country
United States
1
Frequently asked questions
Who invested in Ophirex, Inc.?
Ophirex, Inc. has 1 investors on record on gritt.io and 1 late-stage investors.
When did Ophirex, Inc. last raise funding?
The most recent investment in Ophirex, Inc. recorded on gritt.io was in May 2022.
When was Ophirex, Inc. founded?
Ophirex, Inc. was founded in 2015.
What industry is Ophirex, Inc. in?
Ophirex, Inc. operates in Biotechnology. Find similar Biotechnology investors on gritt.io.
Where is Ophirex, Inc. based?
Ophirex, Inc. is headquartered in Corte Madera, United States.